

International Journal of Environmental Research and Public Health



Article Neighborhood Deprivation and Risks of Autoimmune Disorders: A National Cohort Study in Sweden

Xinjun Li^{1,*}, Jan Sundquist^{1,2,3}, Tsuyoshi Hamano^{4,5} and Kristina Sundquist^{1,2,3}

- ¹ Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden; jan.sundquist@med.lu.se (J.S.); kristina.sundquist@med.lu.se (K.S.)
- ² Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10001, USA
- ³ Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Izumo 690-2406, Japan
- ⁴ Department of Sports Sociology and Health Sciences, Kyoto Sangyo University, Kyoto 520-0461, Japan; thamano@cc.kyoto-su.ac.jp
- ⁵ Department of Functional Pathology, Shimane University School of Medicine, Izumo 690-2406, Japan
- * Correspondence: xinjun.li@med.lu.se; Tel.: +46-40-391381; Fax: +46-40-391370

Received: 5 September 2019; Accepted: 4 October 2019; Published: 9 October 2019



Abstract: Background: No study to date, as far as we know, has analyzed the potential effect of neighborhood-level deprivation on autoimmune disorders (ADs), when adjusted for individual-level characteristics. Methods: A total of 5.4 million individuals from 8363 neighborhoods, comprising the whole Swedish population (ages 25–74 years), were followed for the period 1 January 2000, until admission due to diagnosis of ADs during the period of the study, or the conclusion of the study (31 December 2010). We used a neighborhood deprivation index, constructed from variables such as low education, low income, unemployment, and social welfare assistance, to assess the level of neighborhood deprivation. Multilevel logistic regression was used in the analysis with individual level characteristics at the first level and level of neighborhood deprivation at the second level. Results: A significant association between level of neighborhood deprivation and ADs was found. The crude odds were 1.32 (95% confidence interval 1.27-1.36) for those residing in the high-deprived neighborhoods compared to those living in low-deprivation neighborhoods. In the full model, where individual level characteristics were taken into account, the odds of ADs were 1.18 (1.14–1.22) in the most deprived neighborhoods. Certain Ads—angiitis hypersensitive (5.14), ankylosing spondylitis (1.66), celiac disease (1.65), Crohn's disease (1.21), diabetes mellitus type 1 (1.45), Graves's disease (1.13), Hashimoto thyroiditis (1.51), psoriasis (1.15), rheumatoid arthritis (1.15), sarcoidosis (1.20), and systemic sclerosis (1.27)—remained significantly associated with high level of neighborhood deprivation after adjustment for the individual-level variables. Conclusion: This study is the largest to date analyzing the potential influence of neighborhood deprivation on ADs. Our results indicate that neighborhood deprivation may affect risk of ADs, independent of individual level sociodemographic characteristics. For health care policies, both individual and neighborhood level approaches seem to be of importance.

Keywords: autoimmune disorders; neighborhood deprivation; risk factors; Sweden

1. Introduction

Autoimmune disorders (ADs) are a heterogeneous group of between 70 to 80 specific disorders that affect approximately 3% to 8% of the populations in the United States [1] and the Nordic Countries [2].

The number of individuals affected by ADs is increasing; between 14.7 million to 23.5 million people have Ads, according to previous studies from the U.S. [1,3]. ADs consist of a broad range of disorders, including both autoimmune and inflammatory disorders. Some ADs, such as type 1 diabetes mellitus, may be present as early as in the first decade of life. However, symptoms of most ADs typically become apparent in the third to sixth decade of life [3]. The nature of the etiologies of ADs is largely unknown. A number of risk factors for ADs have been previously mentioned. These include female sex, family history of ADs [4], and socio–economic factors [5–8] including education [9].

Recently, interest has greatly increased concerning the contextual effects of neighborhood deprivation on different health outcomes [10], and the use of multilevel modeling has helped to disentangle the effects of neighborhood characteristics from individual-level risk factors [11,12]. To cite an example, if people living in the same neighborhood share the same socioeconomic environment, access to healthcare, norms settings, and lifestyles, they may characterize a common level of health beyond individual characteristics. Thus, together with individual-level sociodemographic factors, neighborhood-level factors may also increase the risk of many diseases. For example, neighborhood deprivation is associated with several cardiovascular risk factors; it has been shown to be an important independent risk factor for coronary heart disease and other cardiovascular diseases [13–17], psychiatric disorders [18], and certain specific types of ADs [19–21]. There is also a link between cardiovascular diseases and ADs [22]. No study to date, as far as we know, has analyzed the potential effect of neighborhood-level deprivation on ADs, when adjusted for individual-level characteristics.

Our first aim with this study was to investigate whether there is an association between neighborhood deprivation and incidence of ADs. The neighborhoods were derived from small geographic units covering all Sweden. Socio–economic status or level of deprivation of these units was classified as high, middle or low, based on a previously used neighborhood deprivation index (based on low educational status, low income, unemployment, and social welfare assistance). Our second aim was to investigate whether this possible difference stays the same after accounting for individual-level sociodemographic characteristics, and hospitalization for chronic obstructive pulmonary disease and/or alcohol-related diseases.

2. Materials and Methods

The data used in this study were retrieved from registers located at the Center for Primary Health Care Research at Lund University. The dataset used for this study incorporated information on the entire national population that comprised a period of 40 years. It included hospital inpatient and outpatient data for the whole population during the study period. In addition, the dataset incorporated population-wide documentation concerning concomitant factors such as geographical region and socio–economic status. We used the primary diagnoses for ADs in the Swedish In-Patient Register (data are available between 1964–2010) and Out-Patient Register (2001–2010). Additional linkages were carried out on national census data (to gather individual socio–economic status, geographical region of residence, and the other socio–demographic data), The Registry of Cause of Death (to identify date and cause of death; data are available between 1961–2010), and the Immigration Registry (to identify date of emigration). All linkages were performed via use of a personal national ID number that is assigned to each person in Sweden, either at birth or at immigration to the country, and is used throughout their lifetime. To ensure anonymity, a serial number replaced this number for each individual.

The follow-up period commenced on 1 January 2000 and continued until first registration for ADs, death, emigration, or the conclusion of the study period (31 December 2010). Prior to being enrolled into the study, individuals who had previously (i.e., between 1997–1999) been diagnosed with any autoimmune disorders (n = 33,528) were removed from the study in order to exclude pre-existing cases. The study population comprised a nationwide sample of 2,698,818 men and 2,679,542 women aged 25–74 years.

2.1. Outcome Variable

Diagnoses were reported according to the tenth version of the International Classification of Diseases (ICD–10), classified in 43 autoimmune conditions of diseases.

2.2. Individual Variables

Individual variables were defined at the start of the follow-up and included sex, age at the start of the study, marital status, family income, educational attainment, immigration status, geographical region, and mobility of the subjects. Hospitalization for chronic lower respiratory diseases, alcoholism, and related liver disease were defined during the study period.

2.3. Sex. Male and Female

Age. Age was divided into 10-year categories. Age was used as a continuous variable in the adjustment.

Marital status. Individuals were classified as married/cohabitating or single (never married, widowed or divorced).

Family income by quartile. Statistics Sweden provided the information on family income (2000) that was obtained from the Total Population Register. We used the distribution to calculate empirical quartiles.

Educational attainment. Educational attainment was classified as level of education \leq 9 years, 10–12 years, or > 12 years.

2.4. Immigration Status: (1) Born in Sweden and (2) Born outside Sweden

Region of residence: Large cities (Stockholm, Gothenburg, Malmö), southern Sweden, and northern Sweden.

Move: Length of years spent living in a neighborhood, categorized as moved (lived in neighborhood < 5 years) or not moved (lived in neighborhood > 5 years). The rationale for adjusting for mobility is because mobility may have an influence on the exposure, i.e., neighborhood deprivation.

Hospitalization for chronic obstructive pulmonary disease (COPD) was identified in the Hospital Registry (ICD-10 = J40–J49). Patients' COPD status in the Hospital Registry was individually linked to their ADs status via usage of a serial number (see above). Hospitalization for alcoholism and related liver disease was also identified in the Hospital Registry according to the International Classification of Diseases (ICD) codes (ICD–10 = F10 and K70).

Neighborhood Deprivation Index: We used a summary measure to characterize neighborhood-level deprivation. Deprivation indicators used by past studies were identified to characterize neighborhood environments; we then used a principal components analysis to select deprivation indicators in the Swedish national database [14]. The following four variables were selected for those aged 25–74: low educational status (< 10 years of formal education); low income (income from all sources, including that from interest and dividends, defined as less than 50% of individual median income); unemployment (not employed, excluding full-time students, those completing compulsory military service, and early retirees); and social welfare assistance. Each of the four variables loaded on the first principal component with similar loadings (+ 0.47 to + 0.53) and explained 52% of the variation between these variables. Neighborhood deprivation was assessed in 2000.

As supplied to us by Statistics Sweden, a z score was calculated for each neighborhood, defined based on the geographic units SAMS (Small Areas Market Statistics). The z scores were weighted by the coefficients for the eigenvectors, and then summed to create an index [23]. The index was categorized into three groups: low (index below one standard deviation (SD) from the mean), moderate (index within one SD of the mean), and high (index above one SD from the mean). Higher scores reflected more deprived neighborhoods. A total of 8363 SAMS units were included in our study (Supplementary Table S1).

2.5. Statistical Analysis

Age-standardized cumulative incidence was calculated by direct age standardization using 10-year age groups specific to women or men, with the entire Swedish population of women or men in the year 2000 as the standard population. For the outcome variables, we used multilevel (hierarchical) logistic regression models with incidence proportions (the proportion of adults who became cases among those entered into the study time interval). Analyses were performed using MLwiN, version 2.27. First, a null model was calculated to determine the variance among neighborhoods. A neighborhood model was subsequently then calculated that only included neighborhood-level deprivation to determine the crude odds of ADs incidence by level of neighborhood deprivation (model 1). We next calculated a model that included neighborhood-level deprivation and sex, age (model 2), and eight individual-level sociodemographic variables, added simultaneously to the model (model 3) Finally, a full model was calculated that included neighborhood-level deprivation, all the individual-level sociodemographic variables, and hospitalization for COPD and/or hospitalization for alcoholism and related liver disease, which were added simultaneously to the model (model 4). These full models tested whether neighborhood-level deprivation was significantly associated with ADs when adjusted for the individual characteristics, and whether there were differential effects of neighborhood-level deprivation on ADs across individual characteristics [24], i.e., cross-level interactions.

Random effects: The between-neighborhood variance was estimated both with and without a random intercept. If it was larger than 1.96 times the standard error then it was regarded as significant; this concurs with the precedent established in prior studies [18,25].

There were no meaningful cross-level interactions or effect modifications shown in the test for cross-level interactions between the individual-level variables and neighborhood-level deprivation on odds of ADs. The analyses were therefore performed with both sexes combined.

2.6. Ethical Considerations

The Ethics Committee of Lund University, Sweden approved this study (2012/795).

3. Results

Table 1 shows population sizes and neighborhood characteristics for the year 2000 by neighborhood-level deprivation. In total the number of neighborhoods was 8363 (Supplementary Table S1). Of the total population, 25% (low), 59% (moderate), and 16% (high) lived in the three types of neighborhood. In the follow-up period, there were 82,587 (1.5%) of individuals who were diagnosed with ADs. There were more women than men with ADs in the patient population. Age-adjusted ADs incidence rates were 13.0 per 1000 in neighborhoods with low deprivation, in neighborhoods with moderate deprivation the figure was 15.9 per 1000, and in neighborhoods with high deprivation, it was 17.0 per 1000. A similar pattern of higher ADs with each increasing level of neighborhood-level deprivation was shown across all ten individual-level variable categories, hospitalization for COPD, and hospitalization for alcoholism and related liver disease. Significance tests to make comparisons across neighborhoods are shown in Table 2 and Supplementary Table S2. All categories indicated a gradient effect across level of neighborhood deprivation (Table 2 and Supplementary Table S2).

Table 3 show the ICD codes and the total number of patients with autoimmune diseases. The largest diagnostic groups were diabetes mellitus type 1 (14.6%), and rheumatoid arthritis (9.4%). Age-adjusted incidence rates of diabetes mellitus type 1 were 24.6 per 10,000 in neighborhoods with low deprivation, with moderate deprivation, the figure was 37.9 per 10,000, and in neighborhoods with high deprivation, it was 47.7 per 10,000. For rheumatoid arthritis, the rates were 19.2, 24.4, and 23.2 per 10,000 individuals, respectively.

		Autoimmune Disorder Events								
Individual Variables	Populat	ion	N. of I	Events	Incidence Ra	ites by Neighborhood	Deprivation			
	No.	(%)	No.	(%)	Low	Moderate	High			
Total population (%)	5,378,360				1,316,124 (25%)	3,180,078 (59%)	882,158 (16%)			
Total events			82,587		13.0	15.9	17.0			
Sex										
Male	2,698,818	50.2	36,968	44.8	11.7	14.3	15.2			
Female	2,679,542	49.8	45,619	55.2	14.3	17.4	18.7			
Age (years)										
25–34	1,210,432	22.5	11,301	13.7	8.4	9.5	9.9			
35–44	1,205,477	22.4	12,694	15.4	8.7	10.9	11.9			
45–54	1,213,003	22.6	17,370	21.0	12.1	14.8	16.3			
55-64	1,020,846	19.0	20,283	24.6	16.7	20.5	22.7			
65–74	728,602	13.5	20,939	25.4	26.2	28.8	31.4			
Family income										
Low income	1,345,419	25.0	20,263	24.5	13.8	16.9	16.9			
Middle-low income	1,345,830	25.0	23,800	28.8	14.7	17.9	19.1			
Middle-high income	1,344,824	25.0	21,286	25.8	13.6	15.9	16.7			
High income	1,342,287	25.0	17,238	20.9	11.6	13.2	13.7			
Marital status	, ,		,							
Married/cohabiting	2,773,647	51.6	42,637	51.6	12.3	14.9	15.4			
Never married, Widowed, or divorced	2.604.713	48.4	39,950	48.4	14.6	17.2	18.5			
Immigrant status	, ,		,							
Sweden	4.624.597	86.0	72.280	87.5	13.2	16.1	17.7			
Other countries	753,763	14.0	10,307	12.5	11.5	14.4	15.3			
Educational attainment	,		,							
< 9 years	849,993	15.8	20,589	24.9	14.9	16.9	17.6			
10–12 years	552,451	10.3	8823	10.7	14.9	17.6	18.5			
> 12 years	3.975.916	73.9	53,175	64.4	12.5	15.1	16.1			
Region of residence	-,,-			-						
Large cities	2.720.123	50.6	40.711	49.3	12.9	16.2	17.0			
Southern Sweden	1.789.149	33.3	27.601	33.4	13.4	15.4	16.6			
Norther Sweden	869,088	16.2	14,275	17.3	13.0	16.2	17.9			
Move			,							
Not moved	3.778.649	70.3	62,069	75.2	12.9	15.8	16.9			
Moved	1.599.711	29.7	20.518	24.8	13.2	16.4	17.3			

Table 1. Distribution of population,	number of autoimmune disorder	events, and age-standardiz	ed incidence (per 1000) b	y neighborhood-level	deprivation.

		Autoimmune Disorder Events								
Individual Variables	Populat	ion	N. of I	Events	Incidence Rates by Neighborhood Deprivation					
_	No.	(%)	No.	(%)	Low	Moderate	High			
Hospitalization of chronic lower respiratory										
disease										
No	5,259,280	97.8	77,417	93.7	12.6	15.4	16.3			
Yes	119,080	2.2	5170	6.3	36.8	39.3	38.7			
Hospitalization of alcoholism and related										
liver disease										
No	5,261,431	97.8	79,175	95.9	12.8	15.6	16.6			
Yes	116.929	2.2	3412	4.1	27.6	28.9	27.4			

Table 1. Cont.

	Neighborhood Deprivation								
Individual variables (n =	Low : 17,111)	$Mod \\ (n = 5)$	erate 0,496)	Hi (n = 14)	gh 1,980)	<i>p</i> -Value			
No.	%	No.	%	No.	%	_			
Gender						0.263			
Male 7565	44.2	22,669	44.9	6734	45.0				
Female 9546	55.8	27,827	55.1	8246	55.0				
Age (years)						< 0.001			
25–34 2386	13.9	6727	13.3	2188	14.6				
35–44 2743	16.0	7564	15.0	2387	15.9				
45–54 3757	22.0	10,610	21.0	3003	20.0				
55-64 4304	25.2	12,526	24.8	3453	23.1				
65–74 3921	22.9	13,069	25.9	3949	26.4				
Family income						< 0.001			
Low income 2505	14.6	12.512	24.8	5246	35.0				
Middle-low income 3899	22.8	15.084	29.9	4817	32.2				
Middle-high income 4759	27.8	13,268	26.3	3259	21.8				
High income 5948	34.8	9632	19.1	1658	11.1				
Marital status						< 0.001			
Married/cohabiting 10,133	59.2	26,128	51.7	6376	42.6				
Never married, Widowed, or divorced 6978	40.8	24,368	48.3	8604	57.4				
Immigrant status						< 0.001			
Sweden 15.542	90.8	45.579	90.3	11,159	74.5				
Other countries 1569	9.2	4917	9.7	3821	25.5				
Educational attainment						< 0.001			
\leq 9 years 2492	14.6	13,203	26.1	4894	32.7				
10–12 1435	8.4	5459	10.8	1929	12.9				
>12 years 13,184	77.0	31,834	63.0	8157	54.5				
Region of residence						< 0.001			
Large cities 10,855	63.4	22,211	44.0	7645	51.0				
Southern Sweden 4312	25.2	18,664	37.0	4625	30.9				
Northern Sweden 1944	11.4	9621	19.1	2710	18.1				
Move						< 0.001			
Not moved 12,951	75.7	38,544	76.3	10,574	70.6				
Moved 4160	24.3	11,952	23.7	4406	29.4				
Hospitalization of chronic lower respiratory disease						< 0.001			
No 16,224	94.8	47,355	93.8	13,838	92.4				
Yes 887	5.2	3141	6.2	1142	7.6				
Hospitalization of alcoholism and related liver disease						< 0.001			
No 16,558	96.8	48,506	96.1	14,111	94.2				
Yes 553	3.2	1990	3.9	869	5.8				

Table 2.	Baseline	characteristics	of events	of autoimmune	disorders in	neighborhoods.

Table 3. Number of autoimmune disorder events, and age-standardized incidence (per 10,000 individuals) by neighborhood-level deprivation.

Autoimmune Disorder	ICD-10 Code	N. of E	vents	Incidence Rates by Neighborhood Deprivation			
		No.	%	Low	Moderate	High	
Addison disease	E27.1, E27.2	593	0.41	1.22	1.05	1.10	
Amyotrophic lateral sclerosis	G12.2	2047	1.46	3.90	3.80	3.68	
Angiitis hypersensitive	M31.0	29	0.02	0.02	0.06	0.09	
Ankylosing spondylitis	M45, M08.1	1021	0.76	1.44	1.97	2.34	
Autoimmune hemolytic anemia	D59.0,D59.1	33	0.02	0.05	0.06	0.09	
Behcet disease	M35.2	98	0.05	0.14	0.14	0.39	
Celiac disease	K90.0	326	0.25	0.43	0.65	0.71	
Chorea minor	I02	3	0.00	0.00	0.01	0.01	
Chronic rheumatic heart disease	105-109	1176	0.75	2.09	1.96	3.16	
Crohn disease	K50	6663	4.92	10.96	12.78	13.10	
Dermatitis Herpetiformis	L13.0	22	0.01	0.05	0.03	0.05	
Diabetes mellitus type I	E10	19,516	14.61	24.63	37.94	47.74	
Discoid lupus erythematosus	L93.0	70	0.06	0.08	0.16	0.10	
Giant-cell arteritis	M31.5,M31.6	2860	2.05	5.36	5.33	5.21	
Glomerluar nephritis chronic	N00,N01	1570	1.13	2.67	2.94	3.22	

Autoimmune Disorder	ICD-10 Code	N. of E	vents	Incidence Rates by Neighborhood Deprivation			
		No.	%	Low	Moderate	High	
Glomerular nephritis acute	N03	399	0.29	0.75	0.75	0.69	
Grave disease	E05.0,E05.5	3139	2.21	5.56	5.75	6.57	
Guillain–Barre Syndrome	G61.0	1065	0.73	2.24	1.89	1.93	
Hashimoto thyroiditis	E03.5,E03.8,E03.9,E06.3	2045	1.59	2.58	4.12	4.48	
Immune thrombocytopenic purpura	D69.3	985	0.70	1.80	1.81	1.95	
Localized scleroderma	L94.0	69	0.05	0.13	0.13	0.14	
Lupoid hepatitis	K75.4	362	0.27	0.65	0.69	0.65	
Multiple sclerosis	G35	4363	3.21	7.90	8.33	7.64	
Myasthenia gravis	G70.0	813	0.59	1.47	1.53	1.51	
Pemphigoid	L12 (not L12.2)	351	0.25	0.59	0.64	0.80	
Pemphigus	L10 (not L10.3 and L10.5)	119	0.06	0.28	0.16	0.36	
Pernicious anemia	D51.0	192	0.13	0.28	0.34	0.52	
Polyarteritis nodosa	M30.0	124	0.08	0.24	0.22	0.26	
Polymyalgia rheumatic	M35.3	3561	2.71	5.47	7.03	6.87	
Polymyositis/dermatomyositis	M33	523	0.38	0.88	0.99	1.05	
Primary biliary cirrhosis	K74.3	554	0.42	0.89	1.08	1.04	
Psoriasis	L40	2382	1.80	3.62	4.66	4.80	
Reiter disease	M02.3	55	0.04	0.09	0.11	0.09	
Rheumatic fever	I00,I01	56	0.05	0.09	0.12	0.06	
Rheumatoid arthritis	M05, M06, M08.0, M08.2	12,343	9.40	19.25	24.42	23.17	
Sarcoidosis	D86	1953	1.51	2.98	3.92	3.57	
Sjögren syndrome	M35.0	549	0.41	0.89	1.05	1.10	
Systemic lupus erythematosus	M32	1306	0.98	2.12	2.53	2.51	
Systemic sclerosis	M34	774	0.58	1.22	1.51	1.51	
Takayasus disease	M31.4	81	0.05	0.13	0.14	0.24	
Thrombotic thrombocytop	M31.1	100	0.08	0.15	0.21	0.14	
Ulcerative colitis	K51	7387	5.41	13.20	14.04	13.43	
Wegener granulomatosis	M31.3	910	0.68	1.50	1.75	1.75	
All		82,587	61.14	130.01	158.79	169.81	

Table 3. Cont.

For individuals living in a high versus low deprivation neighborhood, the odds ratio (OR) of ADs was 1.32 (1.27–1.36) in the crude model (Table 4). High neighborhood-level deprivation remained significantly associated with ADs when adjusted for the ten individual-level variables, hospitalization for COPD, and hospitalization for alcoholism and related liver disease (OR = 1.18; 95% CI, 1.14–1.22). The highest odds of ADs were found in individuals who were male, never married, widowed, or divorced, had the lowest educational attainment, had moved, were hospitalized for COPD, and/or were hospitalized for alcoholism and related liver disease. Individuals who lived in Southern Sweden or immigrants had lower odds of ADs. Interestingly, the highest odds ratios were found among individuals with middle level family income.

Table 5 shows the results for specific ADs. For certain Ads—angiitis hypersensitive, ankylosing spondylitis, celiac disease, Crohn's disease, diabetes mellitus type 1, Graves' disease, Hashimoto thyroiditis, psoriasis, rheumatoid arthritis, sarcoidosis, and systemic sclerosis—the high level of neighborhood deprivation remained significantly associated with those ADs after adjustment for the individual-level variables. Supplementary Figure S1 shows a forest plot of key findings for specific ADs in high level of neighborhood deprivation compared with low level of neighborhood deprivation.

Variables	Model 1				Model 2		Model 3			Model 4			
valiables	OR	95%	CI	OR	DR 95% CI		OR	95% CI		OR	95% CI		<i>p</i> -Value
Neighborhood-level variable (ref. Low)													
Moderate	1.23	1.19	1.26	1.20	1.17	1.23	1.13	1.10	1.16	1.13	1.10	1.16	< 0.001
High	1.32	1.27	1.36	1.31	1.26	1.35	1.20	1.16	1.25	1.18	1.14	1.22	< 0.001
Age				1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.03	< 0.001
Sex to male (ref. female)				1.23	1.20	1.25	1.21	1.18	1.24	1.23	1.20	1.25	< 0.001
Family income (ref. High income)													
Low income							1.23	1.19	1.27	1.20	1.16	1.24	< 0.001
Middle-low income							1.30	1.26	1.34	1.26	1.22	1.30	< 0.001
Middle-high income							1.19	1.15	1.22	1.17	1.14	1.20	< 0.001
Marital status (ref. Married/co-habiting)													
Never married, widowed, or divorced							1.16	1.14	1.19	1.13	1.11	1.15	< 0.001
Immigrant status (ref. Born in Sweden)							0.85	0.83	0.88	0.85	0.83	0.88	< 0.001
Education attainment (ref. > 12 years)													
\leq 9 years							1.13	1.10	1.16	1.12	1.09	1.15	< 0.001
10–12 years							1.15	1.11	1.19	1.13	1.09	1.17	< 0.001
Region of residence (ref. Large cities)													
Southern Sweden							0.95	0.92	0.97	0.96	0.93	0.98	< 0.001
Northern Sweden							0.98	0.95	1.01	0.99	0.96	1.02	0.549
Move (ref. Not moved)							1.07	1.05	1.10	1.06	1.03	1.08	< 0.001
Hospitalization of chronic lower										2.00	2 00	0.17	-0.001
respiratory disease (ref. No)										2.08	2.00	2.17	<0.001
Hospitalization of alcoholism and related										1 74	1.45	1.02	-0.001
liver disease (ref. No)										1./4	1.65	1.83	<0.001
Variance (S.E.)		0.029 (0.003)			0.021 (0.003)		0.018 (0.003)			0.018 (0.003)			
Explained variance (%)		22			43			51			5	51	

Table 4. Odds ratios (OR) and 95% confidence intervals (CI) for autoimmune disorders; Results of multi-level logistic regression models.

Note: Model 1: crude model; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, family income, marital status, country of birth, education, region of residence, and move. Model 4: adjusted for age, sex, family income, marital status, country of birth, education, region of residence, move, and hospitalization of chronic low respiratory disease and alcoholism and related liver disease.

Low, ReferenceModerateHighHighAddison diseaseOR0R95% CI0.895% CIAddison disease1.000.950.851.060.100.881.170.852Anytitis hypersensitive1.003.280.751.43.45.141.162.190.041Aukylosing spondylitis1.001.351.141.601.651.132.04<0.001Autoimume hemolytic anenia1.000.780.321.911.661.352.04<0.001Celiac disease1.001.451.071.971.651.132.400.070Chronic rheumatic heart disease1.000.761.021.120.941.340.223Crohn disease1.000.540.201.460.750.202.730.667Diabetes mellitus type I1.001.790.923.491.130.452.830.800Gianer-cell arteritis1.000.790.823.491.130.452.830.800Giamer-ua rephritis chronic1.001.010.881.151.070.911.260.425Glomerular nephritis chronic1.000.930.751.131.131.160.361Garaves' disease1.001.040.951.131.131.011.270.322Giamerular rephritis chronic1.000.930.751.130.140.961.200.361	Autoimmune Disorders	Neighborhood Deprivation								
OROR 978 OR 978 OR 978 OI Amyotrophic lateral sclenosis1.000.950.851.061.010.881.170.852Angitis hypersensitive1.003.280.7514.345.141.052.5190.041Ankylosing spondylitis1.000.780.321.911.170.403.40 <0.071 Beheet disease1.001.451.071.971.651.32.400.001Celiac disease1.001.451.071.971.651.32.400.001Chronic rheumatic heart disease1.000.761.021.120.941.340.223Crohn disease1.000.540.201.460.750.202.730.667Diabetes mellitus type I1.000.540.201.460.750.202.730.667Diabetes mellitus type I1.000.750.923.491.130.452.830.800Giant-cell arteritis1.000.730.851.021.130.450.4250.455Giomerular nephritis acute1.000.930.731.180.860.611.200.452Giomerular nephritis acute1.000.870.751.010.970.831.190.750.425Giomerular nephritis acute1.000.870.751.010.970.841.340.960.78Guidant-mep		Low, Reference Moderate				- /				
Addison disease 1.00 0.86 0.70 1.04 0.94 0.72 1.22 0.627 Amguttip hypersensitive 1.00 3.28 0.75 14.34 5.14 1.05 25.19 0.044 Ankylosing spondylitis 1.00 1.35 1.14 1.60 1.66 1.35 2.04 <0.001 Autoimmune hemolytic aremia 1.00 0.78 0.32 1.91 1.76 0.40 0.40 0.771 Behçet disease 1.00 1.45 1.07 1.77 1.65 1.13 2.40 0.010 Chorea minor 1.00 - <td< th=""><th></th><th>OR</th><th>OR</th><th>959</th><th>% CI</th><th>OR</th><th>95%</th><th>6 CI</th><th></th></td<>		OR	OR	959	% CI	OR	95%	6 CI		
Amyotrophic lateral sclerosis 1.00 0.85 0.45 1.04 0.85 1.17 0.852 Angilish hypersensitive 1.00 1.35 1.14 1.60 1.66 1.35 2.04 <0.001	Addison disease	1.00	0.86	0.70	1.04	0.94	0.72	1.22	0.627	
Ángittis hypersensitive 1.00 3.28 0.75 14.34 1.51 1.16 1.55 2.519 0.044 Autoimmune hemolytic anemia 1.00 0.78 0.32 1.91 1.17 0.40 3.40 0.771 Behçet disease 1.00 1.07 1.76 1.69 0.92 3.13 0.092 Celiac disease 1.00 1.45 1.07 1.76 1.69 0.92 3.13 0.092 Chora minor 1.00 1.45 1.07 1.21 0.94 1.34 0.223 Crobn disease 1.00 1.24 0.20 1.41 1.38 1.52 <0.001	Amyotrophic lateral sclerosis	1.00	0.95	0.85	1.06	1.01	0.88	1.17	0.852	
Ankylosing spondylitis 1.00 1.35 1.14 1.60 1.66 1.35 2.04 <0.071 Autoimmune hemolytic anemia 1.00 0.78 0.32 1.91 1.17 0.40 3.40 0.771 Behçet disease 1.00 1.45 1.07 1.97 1.69 0.92 3.13 0.092 Ceina clisease 1.00 1.45 1.07 1.97 1.65 1.13 2.40 0.010 Dermatitis Herpetiformis 1.00 0.54 0.20 1.12 1.11 1.31 4.55 2.60 0.60 Diabetes mellitus type I 1.00 1.25 1.21 1.13 1.45 1.38 0.45 2.83 0.800 Glarnt-cell arteritis 1.00 0.39 0.85 1.12 0.94 0.33 0.45 2.83 0.800 Glomerular nephritis chronic 1.00 0.39 0.35 1.13 1.01 1.26 0.425 Glomerular nephritis chronic 1.00 0.393 0.	Angiitis hypersensitive	1.00	3.28	0.75	14.34	5.14	1.05	25.19	0.044	
Autoimmune hemolytic anemia 1.00 0.78 0.32 1.91 1.17 0.40 3.40 0.771 Behçet disease 1.00 1.45 1.76 1.69 0.92 3.13 0.092 Celiac disease 1.00 1.45 1.07 1.67 1.65 1.13 2.40 0.010 Chorea minor 1.00 - <td>Ankylosing spondylitis</td> <td>1.00</td> <td>1.35</td> <td>1.14</td> <td>1.60</td> <td>1.66</td> <td>1.35</td> <td>2.04</td> <td>< 0.001</td>	Ankylosing spondylitis	1.00	1.35	1.14	1.60	1.66	1.35	2.04	< 0.001	
Behçet discase 1.00 1.01 0.59 1.76 1.69 0.92 3.13 0.092 Celiac disease 1.00 1.45 1.77 1.97 1.65 1.13 2.40 0.010 Chronic rheumatic heart disease 1.00 0.88 0.76 1.02 1.12 0.94 1.34 0.223 Ochon disease 1.00 0.54 0.20 1.46 0.75 0.20 2.73 0.657 Diabetes melitus type I 1.00 1.25 1.21 1.31 0.45 2.83 0.80 Giant-cell arteritis 1.00 0.93 0.85 1.02 0.94 0.83 1.06 0.308 Glomerular nephritis acute 1.00 0.93 0.73 1.18 0.86 0.61 1.20 0.361 Graves' disease 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.782 Guilain-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 </td <td>Autoimmune hemolytic anemia</td> <td>1.00</td> <td>0.78</td> <td>0.32</td> <td>1.91</td> <td>1.17</td> <td>0.40</td> <td>3.40</td> <td>0.771</td>	Autoimmune hemolytic anemia	1.00	0.78	0.32	1.91	1.17	0.40	3.40	0.771	
$\begin{array}{c cliac disease}{} 1.00 & 1.45 & 1.07 & 1.97 & 1.65 & 1.13 & 2.40 & 0.010 \\ Chrone minor & 1.00 & .8 & .7 & . & . & . & . & . & . & . & . & $	Behçet disease	1.00	1.01	0.59	1.76	1.69	0.92	3.13	0.092	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Celiac disease	1.00	1.45	1.07	1.97	1.65	1.13	2.40	0.010	
Chronic rheumatic heart disease 1.00 0.88 0.76 1.02 1.12 0.94 1.34 0.223 Crohn disease 1.00 1.14 1.07 1.21 1.21 1.11 1.31 <001	Chorea minor	1.00	-	-	-					
Crohn disease 1.00 1.14 1.07 1.21 1.21 1.11 1.31 < < 0.01 Dermatitis Herpetiformis 1.00 0.54 0.20 1.46 0.75 0.20 2.73 0.657 Diabetes mellitus type I 1.00 1.25 1.21 1.31 1.45 1.38 1.52 < 0.001	Chronic rheumatic heart disease	1.00	0.88	0.76	1.02	1.12	0.94	1.34	0.223	
Dermatiis Herpetiformis 1.00 0.54 0.20 1.46 0.75 0.20 2.73 0.657 Diabetes mellitus type I 1.00 1.27 0.22 3.49 1.13 0.45 2.83 0.800 Giant-cell arteritis 1.00 0.93 0.85 1.02 0.94 0.83 1.06 0.308 Glomerular nephritis curue 1.00 0.93 0.73 1.18 0.66 0.61 1.20 0.361 Guilalin-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimoto thyroiditis 1.00 1.53 1.35 1.72 1.51 1.30 1.76 <0.001	Crohn disease	1.00	1.14	1.07	1.21	1.21	1.11	1.31	< 0.001	
Diabetes mellitus type I 1.00 1.25 1.21 1.31 1.45 1.88 1.52 < < 0.001 Discoid lupue erythematosus 1.00 1.79 0.92 3.49 1.13 0.45 2.83 0.800 Giant-cell arteritis 1.00 0.01 0.89 1.15 1.07 0.91 1.26 0.425 Glomerular nephritis chronic 1.00 0.93 0.85 1.02 0.94 0.83 0.61 1.20 0.361 Grarves' disease 1.00 0.93 0.73 1.13 0.11 0.97 0.80 1.19 0.78 Hashimoto hyroiditis 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.78 Immune thrombocytopenic purpura 1.00 0.87 0.73 1.51 0.90 0.41 1.96 0.78 Localized scleroderma 1.00 0.91 0.78 1.66 1.97 0.68 1.38 0.87 Multiple sclerosis 1.00 1.06	Dermatitis Herpetiformis	1.00	0.54	0.20	1.46	0.75	0.20	2.73	0.657	
Discoid lupus erythematosus 1.00 1.79 0.92 3.49 1.13 0.45 2.83 0.800 Giant-cell arteritis 1.00 0.93 0.85 1.02 0.94 0.83 1.06 0.308 Glomerular nephritis chronic 1.00 1.01 0.89 1.15 1.07 0.91 1.26 0.425 Glomerular nephritis chronic 1.00 0.93 0.73 1.18 0.86 0.61 1.20 0.361 Guillan-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.17 0.642 Localized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.78 Lucalized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.78 0.78 1.15 0.99 0.79 1.16 0.354 Multiple sclerosis 1.00 0.97 0.81 1.15 0.99 0.97 1.25 0.939	Diabetes mellitus type I	1.00	1.25	1.21	1.31	1.45	1.38	1.52	< 0.001	
Giant-cell arteritis 1.00 0.93 0.85 1.02 0.94 0.83 1.06 0.308 Glomerluar nephritis curul 1.00 1.01 0.89 1.15 1.07 0.91 1.26 0.425 Glomerluar nephritis acute 1.00 0.93 0.73 1.18 0.86 0.61 1.20 0.321 Guillain-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimoto thyroiditis 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Localized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.786 Localized scleroderma 1.00 0.44 0.47 1.51 0.90 0.41 1.96 0.786 Multiple sclerosis 1.00 0.46 0.99 1.14 1.05 0.95 1.16 0.334 Myasthenia gravis 1.00 0.97 0.81 1.15 0.98	Discoid lupus erythematosus	1.00	1.79	0.92	3.49	1.13	0.45	2.83	0.800	
Glomerluar nephritis chronic 1.00 1.01 0.89 1.15 1.07 0.91 1.26 0.425 Glomerular nephritis acute 1.00 0.93 0.73 1.18 0.86 0.61 1.20 0.361 Graves' disease 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimoto thyroiditis 1.00 0.53 1.35 1.72 1.51 1.30 1.76 <0.01	Giant-cell arteritis	1.00	0.93	0.85	1.02	0.94	0.83	1.06	0.308	
Glomerular nephritis acute 1.00 0.93 0.73 1.18 0.86 0.61 1.20 0.361 Graves' disease 1.00 1.04 0.95 1.13 1.13 1.01 1.27 0.032 Guillain-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimoto thyroiditis 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Localized scleroderma 1.00 0.91 0.78 1.06 0.95 0.77 1.17 0.642 Localized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.786 Lupoid hepatitis 1.00 1.06 0.99 1.14 1.05 0.95 1.16 0.354 Myasthenia gravis 1.00 0.87 0.66 1.15 0.98 0.70 1.38 0.916 Pemphigoid 1.00 0.50 0.32 0.78 0.83 0.49	Glomerluar nephritis chronic	1.00	1.01	0.89	1.15	1.07	0.91	1.26	0.425	
Graves' disease 1.00 1.04 0.95 1.13 1.13 1.01 1.27 0.032 Guillain-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimot thyroiditis 1.00 1.53 1.35 1.72 1.51 1.30 1.76 <0.001	Glomerular nephritis acute	1.00	0.93	0.73	1.18	0.86	0.61	1.20	0.361	
Guillain-Barré Syndrome 1.00 0.87 0.75 1.01 0.97 0.80 1.19 0.789 Hashimoto thyroiditis 1.00 1.53 1.35 1.72 1.51 1.30 1.76 <0.001	Graves' disease	1.00	1.04	0.95	1.13	1.13	1.01	1.27	0.032	
Hashimoto thyroiditis1.001.531.351.721.511.301.76<0.001Immune thrombocytopenic purpura1.000.910.781.060.950.771.170.642Localized scleroderma1.000.840.471.510.900.411.960.786Lupoid hepatitis1.001.040.801.340.970.681.380.857Multiple sclerosis1.000.970.811.150.990.791.250.939Pemphigoid1.000.870.661.150.980.701.380.916Pemphigoid1.000.500.320.780.830.491.390.476Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.001.101.001.201.100.981.230.097Polymyalgia rheumatic1.001.160.931.441.280.961.700.095Primary bilary cirthosis1.001.160.592.291.000.392.550.996Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.251.111.401.201.021.400.024Sjögren syndrome1.001.230.991.531.250.941.660.120Systemic lupus erythematosus1.001.2	Guillain–Barré Syndrome	1.00	0.87	0.75	1.01	0.97	0.80	1.19	0.789	
Immune thrombocy openic purpura 1.00 0.91 0.78 1.06 0.95 0.77 1.17 0.642 Localized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.786 Lupoid hepatitis 1.00 1.04 0.80 1.34 0.97 0.68 1.38 0.857 Multiple sclerosis 1.00 0.97 0.81 1.15 0.99 0.79 1.25 0.939 Pemphigoid 1.00 0.87 0.66 1.15 0.98 0.70 1.38 0.916 Permphigus 1.00 0.50 0.32 0.78 0.83 0.49 1.39 0.476 Permicious anemia 1.00 0.92 6.6 1.35 1.24 0.79 1.95 0.358 Polyarteritis nodosa 1.00 0.92 6.6 1.33 1.08 0.61 1.91 0.786 Polymysitis/dermatomyositis 1.00 1.10 1.00 1.20 1.10 0.98 1.23 0.097 Polymysitis/dermatomyositis 1.00 1.16	Hashimoto thyroiditis	1.00	1.53	1.35	1.72	1.51	1.30	1.76	< 0.001	
Localized scleroderma 1.00 0.84 0.47 1.51 0.90 0.41 1.96 0.786 Lupoid hepatitis 1.00 1.04 0.80 1.34 0.97 0.68 1.38 0.857 Multiple sclerosis 1.00 0.06 0.99 1.14 1.05 0.95 1.16 0.354 Myasthenia gravis 1.00 0.97 0.81 1.15 0.99 0.79 1.25 0.939 Pemphigoid 1.00 0.87 0.66 1.15 0.98 0.70 1.38 0.916 Permphigus 1.00 0.50 0.32 0.78 0.83 0.49 1.39 0.476 Pernicious anemia 1.00 0.92 0.62 1.35 1.24 0.79 1.95 0.358 Polymyalgia rheumatic 1.00 1.10 1.00 1.20 1.10 0.98 1.23 0.097 Polymyositis/dermatomyositis 1.00 1.16 0.93 1.44 1.28 0.96 1.7	Immune thrombocytopenic purpura	1.00	0.91	0.78	1.06	0.95	0.77	1.17	0.642	
Lupoid hepatitis1.001.040.801.340.970.681.380.857Multiple sclerosis1.001.060.991.141.050.951.160.354Myasthenia gravis1.000.970.811.150.980.791.250.939Pemphigoid1.000.870.661.150.980.701.380.916Pemphigus1.000.500.320.780.830.491.390.476Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.000.860.561.331.080.611.910.786Polymyalgia rheumatic1.001.160.931.441.280.961.700.095Primary biliary cirrhosis1.001.071.061.311.151.001.320.047Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.181.131.241.151.081.22<0.001	Localized scleroderma	1.00	0.84	0.47	1.51	0.90	0.41	1.96	0.786	
Multiple sclerosis 1.00 1.06 0.99 1.14 1.05 0.95 1.16 0.354 Myasthenia gravis 1.00 0.97 0.81 1.15 0.99 0.79 1.25 0.939 Pemphigoid 1.00 0.87 0.66 1.15 0.98 0.70 1.38 0.916 Pemphigus 1.00 0.50 0.32 0.78 0.83 0.49 1.39 0.476 Pernicious anemia 1.00 0.92 0.62 1.35 1.24 0.79 1.95 0.358 Polyarteritis nodosa 1.00 0.10 1.00 1.20 1.10 0.98 1.23 0.097 Polymyalgia rheumatic 1.00 1.10 1.02 1.10 0.98 1.23 0.097 Polymyalgia rheumatic 1.00 1.16 0.93 1.44 1.28 0.96 1.70 0.095 Primary biliary cirrhosis 1.00 1.17 1.06 1.31 1.15 1.00 1.32 0.4	Lupoid hepatitis	1.00	1.04	0.80	1.34	0.97	0.68	1.38	0.857	
Myasthenia gravis1.000.970.811.150.990.791.250.939Pemphigoid1.000.870.661.150.980.701.380.916Pemphigus1.000.500.320.780.830.491.390.476Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.000.920.621.331.080.611.910.786Polymyalgia rheumatic1.001.101.001.201.100.981.230.097Polymyositis/dermatomyositis1.001.160.931.441.280.961.700.095Primary bilary cirrhosis1.001.160.931.441.280.961.700.095Primary bilary cirrhosis1.001.171.061.311.151.001.320.047Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatic farthritis1.001.230.991.531.250.941.660.120Systemic sclerosis1.001.261.051.521.271.001.620.051Takayasu disease1.001.261.051.521.271.001.620.051Takayasu disease1.001.261.05	Multiple sclerosis	1.00	1.06	0.99	1.14	1.05	0.95	1.16	0.354	
Pemphigoid1.000.870.661.150.980.701.380.916Pemphigus1.000.500.320.780.830.491.390.476Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.000.860.561.331.080.611.910.786Polymyalgia rheumatic1.001.101.001.201.100.981.230.097Polymyositis/dermatomyositis1.001.160.931.441.280.961.700.095Primary bilary cirrhosis1.001.171.061.311.151.001.320.047Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatic arthritis1.001.251.111.401.201.021.400.024Siggren syndrome1.001.251.111.401.201.021.400.024Systemic sclerosis1.001.261.051.521.271.001.620.051Takayasu disease1.001.261.051.521.271.001.620.051Takayasu disease1.001.261.051.521.271.001.620.051Thrombotic thrombocytop1.001.200.73 <td>Myasthenia gravis</td> <td>1.00</td> <td>0.97</td> <td>0.81</td> <td>1.15</td> <td>0.99</td> <td>0.79</td> <td>1.25</td> <td>0.939</td>	Myasthenia gravis	1.00	0.97	0.81	1.15	0.99	0.79	1.25	0.939	
Pemphigus1.000.500.320.780.830.491.390.476Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.000.860.561.331.080.611.910.786Polymyalgia rheumatic1.001.101.001.201.100.981.230.097Polymyositis/dermatomyositis1.001.160.931.441.280.961.700.095Primary biliary cirrhosis1.001.080.871.341.000.751.340.989Psoriasis1.001.171.061.311.151.001.320.047Reiter disease1.001.160.972.840.720.242.110.543Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatid arthritis1.001.251.111.401.201.021.400.024Sjögren syndrome1.001.251.111.401.201.400.024Systemic sclerosis1.001.261.051.521.271.001.620.051Takayasu disease1.001.261.051.521.271.001.620.051Takayasu disease1.001.020.732.040.830.401.750.626Ulcerative colitis1.001.020.771.02 <td< td=""><td>Pemphigoid</td><td>1.00</td><td>0.87</td><td>0.66</td><td>1.15</td><td>0.98</td><td>0.70</td><td>1.38</td><td>0.916</td></td<>	Pemphigoid	1.00	0.87	0.66	1.15	0.98	0.70	1.38	0.916	
Pernicious anemia1.000.920.621.351.240.791.950.358Polyarteritis nodosa1.000.860.561.331.080.611.910.786Polyarteritis nodosa1.001.101.001.201.100.981.230.097Polymyositis/dernatomyositis1.001.160.931.441.280.961.700.095Primary biliary cirrhosis1.001.080.871.341.000.751.340.989Psoriasis1.001.171.061.311.151.001.320.047Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatic faver1.001.251.111.401.201.021.400.024Sjögren syndrome1.001.251.111.401.201.021.400.024Systemic lupus erythematosus1.001.261.051.521.271.001.620.051Takayasus disease1.001.261.051.521.271.001.620.051Thrombotic thrombocytop1.001.020.732.040.830.401.750.626Ulcerative colitis1.001.020.941.100.7000.991.550.057	Pemphigus	1.00	0.50	0.32	0.78	0.83	0.49	1.39	0.476	
Polyarteritis nodosa 1.00 0.86 0.56 1.33 1.08 0.61 1.91 0.786 Polymyalgia rheumatic 1.00 1.10 1.00 1.20 1.10 0.98 1.23 0.097 Polymyositis/dermatomyositis 1.00 1.16 0.93 1.44 1.28 0.96 1.70 0.095 Primary biliary cirthosis 1.00 1.08 0.87 1.34 1.00 0.75 1.34 0.989 Psoriasis 1.00 1.16 0.59 2.29 1.00 0.39 2.55 0.996 Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Siggren syndrome 1.00 1.23 0.99 1.53 1.25 0.94 1.66 0.120 Systemic lupus erythematosus 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasu disease 1.00 1.26 1.	Pernicious anemia	1.00	0.92	0.62	1.35	1.24	0.79	1.95	0.358	
Polymyalgia rheumatic 1.00 1.10 1.00 1.20 1.10 0.98 1.23 0.097 Polymyositis/dermatomyositis 1.00 1.16 0.93 1.44 1.28 0.96 1.70 0.095 Primary biliary cirhosis 1.00 1.08 0.87 1.34 1.00 0.75 1.34 0.989 Psoriasis 1.00 1.16 0.59 2.29 1.00 0.32 0.047 Reiter disease 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Sarcoidosis 1.00 1.23 0.99 1.53 1.25 0.94 1.66 0.120 Systemic lupus erythematosus 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62	Polyarteritis nodosa	1.00	0.86	0.56	1.33	1.08	0.61	1.91	0.786	
Polymyositis/dermatomyositis 1.00 1.16 0.93 1.44 1.28 0.96 1.70 0.095 Primary bilary cirrhosis 1.00 1.08 0.87 1.34 1.00 0.75 1.34 0.989 Psoriasis 1.00 1.17 1.06 1.31 1.15 1.00 1.32 0.047 Reiter disease 1.00 1.16 0.59 2.29 1.00 0.39 2.25 0.996 Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Rheumatoid arthritis 1.00 1.25 1.11 1.40 1.20 1.02 1.40 0.024 Sjögren syndrome 1.00 1.23 0.99 1.53 1.25 0.94 1.66 0.120 Systemic lupus erythematosus 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasus disease 1.00 1.26 1.05 1.52 1.27 1.00	Polymyalgia rheumatic	1.00	1.10	1.00	1.20	1.10	0.98	1.23	0.097	
Primary biliary cirrhosis 1.00 1.08 0.87 1.34 1.00 0.75 1.34 0.989 Psoriasis 1.00 1.17 1.06 1.31 1.15 1.00 1.32 0.047 Reiter disease 1.00 1.16 0.59 2.29 1.00 0.39 2.55 0.996 Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Rheumatoid arthritis 1.00 1.25 1.11 1.40 1.20 1.02 1.40 0.024 Sjögren syndrome 1.00 1.25 1.11 1.40 1.20 1.40 0.024 Systemic lupus erythematosus 1.00 1.25 1.11 1.40 1.20 1.40 0.024 Systemic sclerosis 1.00 1.26 1.05 1.52 0.94 1.66 0.120 Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051	Polymyositis/dermatomyositis	1.00	1.16	0.93	1.44	1.28	0.96	1.70	0.095	
Psoriasis1.001.171.061.311.151.001.320.047Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatic arthritis1.001.181.131.241.151.081.22<0.001	Primary biliary cirrhosis	1.00	1.08	0.87	1.34	1.00	0.75	1.34	0.989	
Reiter disease1.001.160.592.291.000.392.550.996Rheumatic fever1.001.450.752.840.720.242.110.543Rheumatid arthritis1.001.181.131.241.151.081.22<0.001	Psoriasis	1.00	1.17	1.06	1.31	1.15	1.00	1.32	0.047	
Rheumatic fever 1.00 1.45 0.75 2.84 0.72 0.24 2.11 0.543 Rheumatid arthritis 1.00 1.18 1.13 1.24 1.15 1.08 1.22 <0.001	Reiter disease	1.00	1.16	0.59	2.29	1.00	0.39	2.55	0.996	
Rheumatoid arthritis 1.00 1.18 1.13 1.24 1.15 1.08 1.22 < 0.001 Sarcoidosis 1.00 1.25 1.11 1.40 1.20 1.02 1.40 0.024 Sjögren syndrome 1.00 1.23 0.99 1.53 1.25 0.94 1.66 0.120 Systemic lupus erythematosus 1.00 1.16 1.01 1.33 1.12 0.93 1.35 0.224 Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasus disease 1.00 1.09 0.61 1.94 1.81 0.92 3.59 0.088 Thrombotic thrombocytop 1.00 1.22 0.73 2.04 0.83 0.40 1.75 0.626 Ulcerative colitis 1.00 1.22 0.94 1.32 1.24 0.99 1.55 0.057	Rheumatic fever	1.00	1.45	0.75	2.84	0.72	0.24	2.11	0.543	
Sarcoidosis 1.00 1.25 1.11 1.40 1.20 1.02 1.40 0.024 Sjögren syndrome 1.00 1.23 0.99 1.53 1.25 0.94 1.66 0.120 Systemic lupus erythematosus 1.00 1.16 1.01 1.33 1.12 0.93 1.35 0.224 Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasus disease 1.00 1.09 0.61 1.94 1.81 0.92 3.59 0.088 Thrombotic thrombocytop 1.00 1.22 0.73 2.04 0.83 0.40 1.75 0.626 Ulcerative colitis 1.00 1.03 0.97 1.09 1.02 0.94 1.10 0.700 Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Rheumatoid arthritis	1.00	1.18	1.13	1.24	1.15	1.08	1.22	< 0.001	
Sjögren syndrome1.001.230.991.531.250.941.660.120Systemic lupus erythematosus1.001.161.011.331.120.931.350.224Systemic sclerosis1.001.261.051.521.271.001.620.051Takayasus disease1.001.090.611.941.810.923.590.088Thrombotic thrombocytop1.001.220.732.040.830.401.750.626Ulcerative colitis1.001.030.971.091.020.941.100.700Wegener granulomatosis1.001.120.941.321.240.991.550.057	Sarcoidosis	1.00	1.25	1.11	1.40	1.20	1.02	1.40	0.024	
Systemic lupus erythematosus 1.00 1.16 1.01 1.33 1.12 0.93 1.35 0.224 Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasus disease 1.00 1.09 0.61 1.94 1.81 0.92 3.59 0.088 Thrombotic thrombocytop 1.00 1.22 0.73 2.04 0.83 0.40 1.75 0.626 Ulcerative colitis 1.00 1.03 0.97 1.09 1.02 0.94 1.10 0.700 Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Sjögren syndrome	1.00	1.23	0.99	1.53	1.25	0.94	1.66	0.120	
Systemic sclerosis 1.00 1.26 1.05 1.52 1.27 1.00 1.62 0.051 Takayasu disease 1.00 1.09 0.61 1.94 1.81 0.92 3.59 0.088 Thrombotic thrombocytop 1.00 1.22 0.73 2.04 0.83 0.40 1.75 0.626 Ulcerative colitis 1.00 1.03 0.97 1.09 1.02 0.94 1.10 0.700 Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Systemic lupus erythematosus	1.00	1.16	1.01	1.33	1.12	0.93	1.35	0.224	
Takayasus disease1.001.090.611.941.810.923.590.088Thrombotic thrombocytop1.001.220.732.040.830.401.750.626Ulcerative colitis1.001.030.971.091.020.941.100.700Wegener granulomatosis1.001.120.941.321.240.991.550.057	Systemic sclerosis	1.00	1.26	1.05	1.52	1.27	1.00	1.62	0.051	
Thrombotic thrombocytop 1.00 1.22 0.73 2.04 0.83 0.40 1.75 0.626 Ulcerative colitis 1.00 1.03 0.97 1.09 1.02 0.94 1.10 0.700 Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Takayasus disease	1.00	1.09	0.61	1.94	1.81	0.92	3.59	0.088	
Ulcerative colitis 1.00 1.03 0.97 1.09 1.02 0.94 1.10 0.700 Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Thrombotic thrombocytop	1.00	1.22	0.73	2.04	0.83	0.40	1.75	0.626	
Wegener granulomatosis 1.00 1.12 0.94 1.32 1.24 0.99 1.55 0.057	Ulcerative colitis	1.00	1.03	0.97	1.09	1.02	0.94	1.10	0.700	
	Wegener granulomatosis	1.00	1.12	0.94	1.32	1.24	0.99	1.55	0.057	

Table 5. Odds ratios (OR) and 95% confidence intervals (CI) for autoimmune disorders *.

Note: * Full adjusted model.

We performed an additional analysis using logistic regression models and Cox regression models, and the results were almost identical (Supplementary Tables S3 and S4).

The association between each of the four deprivation indicators in the neighborhood deprivation index and ADs are shown in Supplementary Table S5.

The between-neighborhood variance (i.e., the random intercept) was over 1.96 times the standard error in all models; this indicates that there were major differences in ADs between neighborhoods after taking into account the neighborhood-level variable as well as the individual-level variables. The neighborhood-level variable accounted for 22% of the between-neighborhood variance in the null model (see Table 4). The explained variance was 51% after we included the individual level variables.

4. Discussion

The main findings of this study are that the odds of ADs are higher among individuals living in deprived neighborhoods than individuals living in affluent neighborhoods. This difference remained significant, even after we adjusted for the ten individual-level sociodemographic variables, hospitalization for COPD, and hospitalization for alcoholism and related liver disease. The present study represents a novel contribution as no previous neighborhood study has focused on several specific types of ADs [19–21]. For specific Ads—angiitis hypersensitive, ankylosing spondylitis, celiac disease, Crohn's disease, diabetes mellitus type 1, Graves' disease, Hashimoto thyroiditis, psoriasis,

rheumatoid arthritis, sarcoidosis, and systemic sclerosis—the high level of neighborhood deprivation remained significantly associated with those ADs after adjustment for the individual-level variables.

Individual-level sociodemographic factors, which indicate socioeconomic inequality [5–9], have been reported to be associated with risk of ADs. However, the causal pathways between neighborhood socioeconomic deprivation and poor health outcomes are not fully understood; several possible mechanisms could lie behind our findings. One possible mediator could be psychological stress [26–30], due to littered and unsafe environments, vandalism, isolation/alienation, and violent crime in deprived neighborhoods [18]. It is possible that the lack of safe environments reduces the possibility to exercise; this may aggravate a healthy lifestyle. In addition, socio–cultural norms, regarding smoking and physical activity, could vary between neighborhoods and impact the health of the residents and the risk for ADs. A Swedish study showed that physical inactivity, obesity, and smoking were more common among individuals that lived in deprived neighborhoods than among individuals that lived in affluent neighborhoods [13]. A study from Denmark found that neighborhood deprivation is associated with participation in a population-based health check, in which increasing neighborhood deprivation was associated with decreasing participation. The authors suggested that there is a need to develop preventative health checks tailored to deprived neighborhoods [31].

Studies have shown that risk factors, such as neighborhood socio–economic status [21], neighborhood income [20], and geographical variation [32], are associated with ADs. Although several studies of ADs have used neighborhood level socioeconomic status as a proxy for individual socioeconomic status, another study that represents one of the few studies on this topic found that, after using hierarchical multilevel modelling and controlling for individual socioeconomic status and ADs remained other covariates, only the association between neighborhood socioeconomic status and ADs remained significant. A Canadian study revealed a significant neighborhood influence on the incidence of Crohn's disease and ulcerative colitis [33]. In the present study, the ORs decreased after adding hospitalization for COPD, alcoholism, and related liver disease to the models, which indicates that the neighborhood influences on ADs could be partly mediated by risk factors, such as smoking and alcohol.

Living in neighborhoods with low social deprivation can be a basis for isolation from health-promoting environments (e.g., safe places to conduct physical exercise and proper housing) and social services. Associations between neighborhood characteristics and different health outcomes were found to be inconsistent in a 2001 Lancet study where wealthy nations were compared [34]. This finding suggests that neighborhood determinants of health are multifaceted. These determinants can include the likes of access to health care, education, and social services. In the U.S., access to these types of services is uneven, as the impact of income inequalities on health are more distinct [35]. A study from the U.S. revealed demographic and environmental factors that affect the incidence and cause of SLE by studying geographical variation and clusters in mortality from the disease [32]. According to the census data, clusters with elevated mortality had higher poverty rates and/or greater concentrations of ethnic Hispanics than those with lower mortality [36]. The spatial variation in poverty, Hispanic ethnicity, and solar radiation partly explained the strong pattern of geographical clustering of mortality from SLE in the U.S. [36].

There are some limitations to our study. For example, in studies concerning neighborhood effects on health, selective residential mobility can cause compositional neighborhood differences [37]. Selective residential mobility is the propensity for people to move to neighborhoods that have characteristics that match their individual characteristics (for example, the propensity for people with low socioeconomic status to move to low socio–economic status neighborhoods). However, we made an adjustment for family income; this enhanced our chances to establish the differences between compositional and contextual effects on ADs. It cannot be ruled out, however, that residual confounding exists. For example, socio–economic status cannot be measured precisely and completely and it is possible that there were confounders that we were not able to control for entirely, including smoking and food habit. Our study also has many strengths. The large cohort included the vast majority of patients with ADs in Sweden during the period of the study; this increased the generalizability of our results.

Another strength is the use of personal identification numbers, which enabled us to follow individuals in different registers, for example, the Immigration Register, which permitted calculation of exact risk time in the additional analyses. Furthermore, the Swedish Total Population Register is highly complete, with very few missing data. Finally, our use of multilevel modeling enabled us to separate neighborhood-level and individual-level effects and permitted us to consider both fixed and random effects in the analyses.

5. Conclusions

Neighborhood deprivation seems to have an independent contribution to ADs, although causality cannot be proven. The neighborhood-level and individual-level variables may cumulatively load against individuals so that the most at-risk individuals would be those who have both individual- and neighborhood-level risk factors. These findings raise important clinical and public health concerns, and indicate that both individual- and neighborhood-level approaches are important in health care policies. In addition, possible pathways from neighborhood deprivation to AD need to be studied in detail in order to address the etiology behind neighborhood differences in AD risk.

Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/16/20/3798/s1, Table S1: Population sizes and neighborhood characteristics by neighborhood-level deprivation; Table S2: Baseline characteristics of study population in neighborhoods; Table S3: Odds ratio (OR) and 95% confidence intervals (CI) for autoimmune disorders; Results of logistics regression models; Table S4: Hazard ratios (HR) and 95% confidence intervals (CI) for autoimmune disorders; Results of Cox regression models; Table S5: Odds ratio (OR) and 95% confidence intervals (CI) for autoimmune disorders; Results of Cox regression models; Table S5: Odds ratio (OR) and 95% confidence intervals (CI) for autoimmune disorders for each of the four deprivation indicators in the neighborhood deprivation index *; Figure S1: Adjusted Odds ratios (OR) for autoimmune disorders for individuals living a high level of neighborhood deprivation compared with low level of neighborhood deprivation. Whiskers are 95% confidence intervals.

Author Contributions: Conceptualization, X.L.; Data curation, J.S. and K.S.; Formal analysis, X.L.; Funding acquisition, J.S. and K.S.; Investigation, X.L.; Methodology, X.L.; Project administration, J.S., T.H. and K.S.; Validation, X.L.; Writing—original draft, X.L.; Writing—review & editing, X.L., J.S., T.H. and K.S.

Funding: This research received no external funding.

Acknowledgments: The authors wish to thank the CPF's Science Editor Patrick Reilly for his useful comments on the text. This work was supported by Crafoordska (20171054), to Kristina Sundquist from The Swedish Research Council; ALF funding from Region Skåne and the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL116381.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Dooley, M.; Hogan, S. Environmental Epidemiology and Risk Factors for Autoimmune Disease. *Curr. Opin. Rheumatol.* **2003**, *15*, 99–103. [CrossRef] [PubMed]
- 2. Eaton, W.W.; Rose, N.R.; Kalaydjian, A.; Pedersen, M.G.; Mortensen, P.B. Epidemiology of autoimmune diseases in Denmark. *J. Autoimmun.* 2007, *29*, 1–9. [CrossRef] [PubMed]
- 3. National institutes of Health. *Progress in Autoimmune Diseases Research;* National Institute of Health: Bethesda, MD, USA, 2005.
- 4. Hemminki, K.; Li, X.; Sundquist, J.; Hillert, J.; Sundquist, K. Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions. *Neurogenetics* **2009**, *10*, 5–11. [CrossRef]
- Bernstein, C.N.; Kraut, A.; Blanchard, J.F.; Rawsthorne, P.; Yu, N.; Walld, R. The relationship between inflammatory bowel disease and socioeconomic variables. *Am. J. Gastroenterol.* 2001, *96*, 2117–2125. [CrossRef] [PubMed]
- 6. Alic, M. Socioeconomics of Crohn's disease: A review of epidemiology and an etiological hypothesis. *Am. J. Gastroenterol.* **2000**, *95*, 324–326. [CrossRef]
- Li, X.; Hemminki, K.; Sundquist, K. Regional, socioeconomic and occupational groups and risk of hospital admission for multiple sclerosis: A cohort study in Sweden. *Mult. Scler.* 2008, 14, 522–529. [CrossRef] [PubMed]

- 8. Calixto, O.J.; Anaya, J.M. Socioeconomic status. The relationship with health and autoimmune diseases. *Autoimmun Rev.* **2014**, *13*, 641–654. [CrossRef]
- Li, X.; Sundquist, J.; Sundquist, K. Educational level and occupation as risk factors for inflammatory bowel diseases: A nationwide study based on hospitalizations in Sweden. *Inflamm. Bowel Dis.* 2009, 15, 608–615. [CrossRef]
- 10. Pickett, K.E.; Pearl, M. Multilevel analyses of neighbourhood socioeconomic context and health outcomes: A critical review. *J. Epidemiol. Community Health* **2001**, *55*, 111–122. [CrossRef]
- 11. Diez-Roux, A.V. Multilevel analysis in public health research. *Annu. Rev. Public Health.* **2000**, *21*, 171–192. [CrossRef]
- 12. Duncan, C.; Jones, K.; Moon, G. Context, composition and heterogeneity: Using multilevel models in health research. *Soc. Sci. Med.* **1998**, *46*, 97–117. [CrossRef]
- 13. Sundquist, J.; Malmstrom, M.; Johansson, S.E. Cardiovascular risk factors and the neighbourhood environment: A multilevel analysis. *Int J. Epidemiol.* **1999**, *28*, 841–845. [CrossRef] [PubMed]
- 14. Winkleby, M.; Sundquist, K.; Cubbin, C. Inequities in CHD incidence and case fatality by neighborhood deprivation. *Am. J. Prev. Med.* **2007**, *32*, 97–106. [CrossRef] [PubMed]
- 15. Winkleby, M.A.; Cubbin, C. Influence of individual and neighbourhood socioeconomic status on mortality among black, Mexican-American, and white women and men in the United States. *J. Epidemiol. Community Health* **2003**, *57*, 444–452. [CrossRef]
- Crump, C.; Sundquist, K.; Sundquist, J.; Winkleby, M.A. Neighborhood deprivation and psychiatric medication prescription: A Swedish national multilevel study. *Ann. Epidemiol.* 2011, 21, 231–237. [CrossRef] [PubMed]
- Sundquist, J.; Li, X.; Ohlsson, H.; Råstam, M.; Winkleby, M.; Sundquist, K.; Crump, C. Familial and neighborhood effects on psychiatric disorders in childhood and adolescence. *J. Psychiatr. Res.* 2015, 66–67, 7–15. [CrossRef] [PubMed]
- 18. Sundquist, J.; Johansson, S.E.; Yang, M.; Sundquist, K. Low linking social capital as a predictor of coronary heart disease in Sweden: A cohort study of 2.8 million people. *Soc. Sci. Med.* **2006**, *62*, 954–963. [CrossRef]
- Puett, R.C.; Lamichhane, A.P.; Nichols, M.D.; Lawson, A.B.; Standiford, D.A.; Liu, L.; Liese, A.D. Neighborhood context and incidence of type 1 diabetes: The SEARCH for Diabetes in Youth study. *Health Place* 2012, *18*, 911–916. [CrossRef]
- 20. Chen, C.H.; Huang, K.Y.; Wang, J.Y.; Huang, H.B.; Chou, P.; Lee, C.C. Combined effect of individual and neighbourhood socioeconomic status on mortality of rheumatoid arthritis patients under universal health care coverage system. *Fam. Pract.* **2015**, *32*, 41–48. [CrossRef]
- 21. Trupin, L.; Tonner, M.C.; Yazdany, J.; Julian, L.J.; Criswell, L.A.; Katz, P.P.; Yelin, E. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. *J. Rheumatol.* **2008**, 35, 1782–1788.
- 22. Zoller, B.; Li, X.; Sundquist, J.; Sundquist, K. Risk of pulmonary embolism in patients with autoimmune disorders: A nationwide follow-up study from Sweden. *Lancet* **2012**, *379*, 244–249. [CrossRef]
- 23. Gilthorpe, M.S. The importance of normalisation in the construction of deprivation indices. *J. Epidemiol. Community Health.* **1995**, 49 (Suppl. 2), S45–S50. [CrossRef] [PubMed]
- 24. Goldstein, H. Multilevel Statistical Models, 3rd ed.; Hodder Arnold Publishers: London, UK, 2003.
- 25. Johnell, K.; Lindstrom, M.; Sundquist, J.; Eriksson, C.; Merlo, J. Individual characteristics, area social participation, and primary non-concordance with medication: A multilevel analysis. *BMC Public Health* **2006**, *6*, 52. [CrossRef] [PubMed]
- Nygren, M.; Carstensen, J.; Koch, F.; Ludvigsson, J.; Frostell, A. Experience of a serious life event increases the risk for childhood type 1 diabetes: The ABIS population-based prospective cohort study. *Diabetologia* 2015, 58, 1188–1197. [CrossRef] [PubMed]
- 27. Black, P.H.; Garbutt, L.D. Stress, inflammation and cardiovascular disease. *J. Psychosom. Res.* **2002**, *52*, 1–23. [CrossRef]
- 28. Holden, L.; Scuffham, P.; Hilton, M.; Vecchio, N.; Whiteford, H. Psychological distress is associated with a range of high-priority health conditions affecting working Australians. *Aust. N. Z. J. Public Health* **2010**, *34*, 304–310. [CrossRef]
- 29. Mohr, D.C.; Hart, S.L.; Julian, L.; Cox, D.; Pelletier, D. Association between stressful life events and exacerbation in multiple sclerosis: A meta-analysis. *BMJ* **2004**, *328*, 731. [CrossRef]

- 30. Porcelli, B.; Pozza, A.; Bizzaro, N.; Fagiolini, A.; Costantini, M.C.; Terzuoli, L.; Ferretti, F. Association between stressful life events and autoimmune diseases: A systematic review and meta-analysis of retrospective case-control studies. *Autoimmun. Rev.* **2016**, *15*, 325–334. [CrossRef]
- 31. Bender, A.M.; Kawachi, I.; Jorgensen, T.; Pisinger, C. Neighborhood deprivation is strongly associated with participation in a population-based health check. *PLoS ONE* **2015**, *10*, e0129819. [CrossRef]
- 32. Walsh, S.J.; DeChello, L.M. Geographical variation in mortality from systemic lupus erythematosus in the United States. *Lupus* **2001**, *10*, 637–646. [CrossRef]
- Blanchard, J.F.; Bernstein, C.N.; Wajda, A.; Rawsthorne, P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. *Am. J. Epidemiol.* 2001, 154, 328–335.
 [CrossRef] [PubMed]
- 34. Lynch, J.; Smith, G.D.; Hillemeier, M.; Shaw, M.; Raghunathan, T.; Kaplan, G. Income inequality, the psychosocial environment, and health: Comparisons of wealthy nations. *Lancet* **2001**, *358*, 194–200. [CrossRef]
- 35. Lochner, K.; Pamuk, E.; Makuc, D.; Kennedy, B.P.; Kawachi, I. State-level income inequality and individual mortality risk: A prospective, multilevel study. *Am. J. Public Health* **2001**, *91*, 385–391. [PubMed]
- Walsh, S.J.; Gilchrist, A. Geographical clustering of mortality from systemic lupus erythematosus in the United States: Contributions of poverty, Hispanic ethnicity and solar radiation. *Lupus* 2006, 15, 662–670. [CrossRef] [PubMed]
- 37. Van Ham, M.; Manley, D.; Bailey, N.; Simpson, L.; Maclennan, D. *Neighbourhood Effects Research: New Perspectives*; Springer: Amsterdam, The Netherlands, 2012.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).